Abstract
Aromatase Inhibitors (AI) inhibit the metabolism of androgens into estrogens. Third generation AI are more potent and more specific than the previous ones. They can be divided in two classes, the steroidal and non-steroidal AI; they are active in postmenopausal breast cancer patients. Two non-steroidal AI (Anastrozole and Letrozole) have been compared to Tamoxifen as first line hormone therapy in metastatic breast cancer; they are at least as effective and probably more, and better tolerated than Tamoxifen; however no change in overall survival has been observed. A phase III trial is ongoing with the steroidal AI Exemestane.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
